DiaMedica Therapeutics Inc.

1.69-0.0100-0.59%Vol 57.73K1Y Perf -49.70%
Aug 5th, 2022 15:59 DELAYED
BID1.66 ASK1.75
Open1.72 Previous Close1.70
Pre-Market- After-Market1.70
 - -  0.01 0.59%
Target Price
11.40 
Analyst Rating
Strong Buy 1.50
Potential %
574.56 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
★★★★★ —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Price Range Ratio 52W %
14.71 
Earnings Rating
Strong Buy
Market Cap20.21M 
Earnings Date
10th Aug 2022
Alpha0.22 Standard Deviation1.74
Beta3.21 

Today's Price Range

1.661.72

52W Range

1.154.82

5 Year PE Ratio Range

-3.80-8.10

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
2.42%
1 Month
-16.34%
3 Months
-34.50%
6 Months
-38.99%
1 Year
-49.70%
3 Years
-45.13%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
DMAC1.69-0.0100-0.59
AAPL165.35-0.2300-0.14
GOOG118.22-0.6500-0.55
MSFT282.91-0.7400-0.26
XOM88.451.26001.45
WFC43.760.99002.31
JNJ171.11-0.6800-0.40
FB196.640.99000.51
GE74.360.69000.94
JPM115.763.40003.03
 
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.20-0.1335.00
Q04 2021-0.16-0.1037.50
Q03 2021-0.23-0.1821.74
Q02 2021-0.19-0.1710.53
Q01 2021-0.23-0.1917.39
Q04 2020-0.18-0.23-27.78
Q03 2020--0.19-
Q02 2020--0.17-
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.1630.43Positive
9/2022 QR-0.1837.93Positive
12/2022 FY-0.6833.98Positive
12/2022 FY-1.100.00-
Next Report Date10th Aug 2022
Estimated EPS Next Report-0.16
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume57.73K
Shares Outstanding11.96K
Shares Float26.05M
Trades Count282
Dollar Volume97.77K
Avg. Volume151.60K
Avg. Weekly Volume44.92K
Avg. Monthly Volume277.82K
Avg. Quarterly Volume132.07K

DiaMedica Therapeutics Inc. (NASDAQ: DMAC) stock closed at 1.69 per share at the end of the most recent trading day (a -0.59% change compared to the prior day closing price) with a volume of 57.73K shares and market capitalization of 20.21M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 9 people. DiaMedica Therapeutics Inc. CEO is Rick Pauls.

The one-year performance of DiaMedica Therapeutics Inc. stock is -49.7%, while year-to-date (YTD) performance is -54.69%. DMAC stock has a five-year performance of %. Its 52-week range is between 1.15 and 4.82, which gives DMAC stock a 52-week price range ratio of 14.71%

DiaMedica Therapeutics Inc. currently has a PE ratio of -2.20, a price-to-book (PB) ratio of 0.83, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -40.49%, a ROC of -42.08% and a ROE of -42.18%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from DiaMedica Therapeutics Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.16 for the next earnings report. DiaMedica Therapeutics Inc.’s next earnings report date is 10th Aug 2022.

The consensus rating of Wall Street analysts for DiaMedica Therapeutics Inc. is Strong Buy (1.5), with a target price of $11.4, which is +574.56% compared to the current price. The earnings rating for DiaMedica Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

DiaMedica Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

DiaMedica Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 15.30, ATR14 : 0.14, CCI20 : 114.79, Chaikin Money Flow : 0.23, MACD : -0.05, Money Flow Index : 87.32, ROC : 30.50, RSI : 72.18, STOCH (14,3) : 93.50, STOCH RSI : 0.91, UO : 65.54, Williams %R : -6.50), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of DiaMedica Therapeutics Inc. in the last 12-months were: Amy Burroughs (Buy at a value of $141 593), Dietrich John Pauls (Buy at a value of $15 700), Harry W. Alcorn (Buy at a value of $185 067), Richard D. Pilnik (Buy at a value of $49 064), Scott Kellen (Buy at a value of $31 463)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (75.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (25.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.50
Strong Buy
1.00
Strong Buy
1.00

DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. It is principally engaged in the business activity of developing treatments for unmet clinical need or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.

CEO: Rick Pauls

Telephone: +1 763 496-5454

Address: Two Carlson Parkway, Minneapolis 55447, MN, US

Number of employees: 9

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

56%44%

Bearish Bullish

63%38%

Bearish Bullish

52%48%


News

Stocktwits